卵巢癌是妇科肿瘤中死亡率最高的恶性肿瘤 ,其病变隐匿 ,早期诊断困难 ,2 /3以上的患者确诊时已属晚期 ,治疗效果差 ,预后不良。虽然手术技术不断提高 ,术后治疗以铂剂为主联合化疗 ,但患者的 5年生存率仅 19.0 %～ 38.7% [1] 。因此 ,除常规手术联合化疗外 ,还应采取联合免疫 Ovarian cancer is the most serious malignant tumor in gynecological tumors. The lesions are occult and early diagnosis is difficult. More than two thirds of the patients have been diagnosed as having advanced stage, the treatment effect is poor and the prognosis is poor. Although surgical techniques continue to improve, postoperative treatment with platinum-based chemotherapy, but the patients 5-year survival rate was only 19.0% to 38.7% [1]. Therefore, in addition to conventional surgery combined with chemotherapy, but also should take co-immunization